Evidence map›Paper›PMID 41968108›Full record

ArticleJournal of applied microbiology2026

Peptoid-based antimicrobial strategies against polymyxin-resistant Gram-negative bacteria.

Shyam Kumar Mishra, Jiawei Shen, Tanzina Akter, Abiye Tigabu, Umme Laila Urmi, Meseret Alem Damtie, Elias Shiferaw Mekonen, Rajesh Kuppusamy, Kristian Sørensen, Jennifer S Lin and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of applied microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shyam Kumar MishraSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-3888-7319
Jiawei ShenSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Tanzina AkterSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Abiye TigabuSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Umme Laila UrmiSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Meseret Alem DamtieSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Elias Shiferaw MekonenSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Rajesh KuppusamySchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Kristian SørensenDepartment of Bioengineering, School of Medicine and School of Engineering, Stanford University, Stanford, CA 94305, USA.
Jennifer S LinDepartment of Bioengineering, School of Medicine and School of Engineering, Stanford University, Stanford, CA 94305, USA.
Edgar H H WongSchool of Chemical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW 2052, Australia.
Alex HuiSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Annelise E BarronDepartment of Bioengineering, School of Medicine and School of Engineering, Stanford University, Stanford, CA 94305, USA.
Mark WillcoxSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0003-3842-7563

Funding

Role of Innate Immune Dysregulation in the Etiology of DementiaDP1AG072438 · NIA · STANFORD UNIVERSITY · PI BARRON, ANNELISE EMILY · 2020 to 2024
$5.2M
AEBCiscoNHMRC APP1183597NIA NIH HHS DP1 AG072438NIH HHS 1DP1NIH HHS OD029517SENS Research FoundationSilicon Valley Community FoundationStanford University
6 · The paper itself

Abstract

aimsPolymyxins remain the mainstay antibiotic for the treatment of infections caused by multidrug-resistant bacteria. However, with the increase in the use of polymyxins, the simultaneous rise of polymyxin-resistance cases has been another global threat, necessitating the need for novel therapeutic strategies. This work aimed to evaluate the antibacterial activity of cationic peptoids against polymyxin-resistant bacteria of global priority. METHODS AND

resultsThree paired polymyxin-sensitive/polymyxin-resistant strains were included, along with two clinical isolates and one reference strain. Out of nine cationic peptoids, TM8 showed the most potent activity against the polymyxin-resistant bacteria with a geometric mean minimum inhibitory concentration (MIC) of 15.6 μg mL-1. The MIC of TM8 was 2-fold higher in polymyxin-resistant cases. TM8 synergized with colistin, rifampicin, and ciprofloxacin in polymyxin-resistant bacteria with reductions in MIC of antibiotics ranging from 8- to 64-fold. Enterobacter cloacae did not develop resistance to TM8 upon repeated subpassage at its sub-MIC, whereas it evolved to resist ciprofloxacin by sixty-four-fold under the same conditions. A concentration-dependent membrane-disruptive potential activity was noted in flow cytometry using live-dead staining. The impact of monovalent cations was small (≤2-fold change), while in the presence of divalent cations, the MIC of TM8 increased up to 4-fold.

conclusionThis study presents TM8 as a potential candidate antimicrobial against polymyxin-resistant bacteria. Further studies are recommended focusing on safety, pharmacokinetics, and pharmacodynamics of this compound.

Indexed as

Anti-Bacterial AgentsGram-Negative BacteriaPeptoidsPolymyxinsCiprofloxacinColistinDrug Resistance, BacterialDrug Resistance, Multiple, BacterialDrug SynergismHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsCiprofloxacinColistinPeptoidsPolymyxinsantimicrobial peptoidantimicrobial resistancepeptidomimeticpolymyxinsynergy

Identifiers

PMID41968108
PMCPMC13116114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.